{"title":"将病原生物菌株作为活体生物治疗产品供人类使用的可行性","authors":"Pengfei Jin, Xiong Lin, Wenfeng Xu, Kangning Li, Xiaoxiao Zhao, Sirui Guo, Zinan Zhao, Lujie Jiang, Feng Liao, Longgang Chang, Min Wang, Yanmin Liu, Shaolei Huang, Zhangran Chen, Fusui Ji","doi":"10.1002/imt2.202","DOIUrl":null,"url":null,"abstract":"<p>The evaluation of pathobiome strains should be conducted at the strain level, involving the identification of the functional genes, while considering the impact of ecological niche and drug interactions. The safety, efficacy, and quality management of live biotherapeutic products (LBPs), especially pathobiome strains, have certain peculiarities. Promising development methods include the recombinant LBP and active metabolites.\n <figure>\n <div><picture>\n <source></source></picture><p></p>\n </div>\n </figure></p>","PeriodicalId":73342,"journal":{"name":"iMeta","volume":"3 3","pages":""},"PeriodicalIF":23.7000,"publicationDate":"2024-05-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/imt2.202","citationCount":"0","resultStr":"{\"title\":\"The feasibility of using pathobiome strains as live biotherapeutic products for human use\",\"authors\":\"Pengfei Jin, Xiong Lin, Wenfeng Xu, Kangning Li, Xiaoxiao Zhao, Sirui Guo, Zinan Zhao, Lujie Jiang, Feng Liao, Longgang Chang, Min Wang, Yanmin Liu, Shaolei Huang, Zhangran Chen, Fusui Ji\",\"doi\":\"10.1002/imt2.202\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p>The evaluation of pathobiome strains should be conducted at the strain level, involving the identification of the functional genes, while considering the impact of ecological niche and drug interactions. The safety, efficacy, and quality management of live biotherapeutic products (LBPs), especially pathobiome strains, have certain peculiarities. Promising development methods include the recombinant LBP and active metabolites.\\n <figure>\\n <div><picture>\\n <source></source></picture><p></p>\\n </div>\\n </figure></p>\",\"PeriodicalId\":73342,\"journal\":{\"name\":\"iMeta\",\"volume\":\"3 3\",\"pages\":\"\"},\"PeriodicalIF\":23.7000,\"publicationDate\":\"2024-05-26\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://onlinelibrary.wiley.com/doi/epdf/10.1002/imt2.202\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"iMeta\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1002/imt2.202\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"MICROBIOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"iMeta","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/imt2.202","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"MICROBIOLOGY","Score":null,"Total":0}
The feasibility of using pathobiome strains as live biotherapeutic products for human use
The evaluation of pathobiome strains should be conducted at the strain level, involving the identification of the functional genes, while considering the impact of ecological niche and drug interactions. The safety, efficacy, and quality management of live biotherapeutic products (LBPs), especially pathobiome strains, have certain peculiarities. Promising development methods include the recombinant LBP and active metabolites.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
